Quantitative mycotoxin detection in grain extracts using UPLC-MS/MS
Advanced UPLC-MS/MS technology offers superior sensitivity and specificity for detecting mycotoxins in food matrices compared to traditional HPLC with UV detection, enhancing method development and sample analysis efficiency.
Overview
This innovative solution enhances the quantitative determination of mycotoxins in various food matrices, leveraging UPLC-MS/MS technology. It promises superior sensitivity and specificity compared to traditional HPLC with UV detection, making it an ideal choice for analyzing mycotoxins in grains, peanut butter, and wheat flour. The use of UPLC significantly reduces solvent consumption, offering an eco-friendly and efficient analytical process with faster method development and shorter run times.
Technical specifications
Key features:
- Utilizes UPLC for higher sensitivity and eco-friendly operations with reduced solvent use.
- Employs mass spectrometry for superior selectivity and specificity over UV detection.
- Designed for comprehensive detection of various mycotoxins, including aflatoxins, ochratoxin A, fumonisins, deoxynivalenol, and zearalenone.
- Method development and validation are conducted using a Shimadzu LC-30 system with a Sciex Triple Quad 6500+ platform.
- Incorporates stable isotope dilution assay for precise quantification.
Technology readiness level
This technology is currently at TRL 2, indicating that the concept and application have been formulated, and method validation is underway using industry-standard protocols and platforms.
About BioNotus
BioNotus is a GLP-certified contract research organization based in Niel, Belgium, that specializes in providing integrated solutions for drug discovery and development. Founded in 2017, the company offers a unique, combined portfolio of services encompassing bioanalysis, pharmacometrics, and discovery ADMET profiling. Its laboratory is equipped for LC-MS/MS-based bioanalysis to quantify drugs, metabolites, and biomarkers in diverse biological matrices, while its pharmacometrics division utilizes computational modeling and simulation, including population and physiology-based pharmacokinetic (PBPK) approaches, to guide clinical study design and dosing strategies. By offering both laboratory and consulting capabilities under one roof, BioNotus aims to enhance project efficiency and data-driven decision-making for its clients.
The company serves a wide range of partners, including university hospitals, academic researchers, and small-to-medium-sized pharmaceutical and biotech firms. By converting complex experimental data into actionable insights, BioNotus helps clients navigate regulatory requirements, optimize dosing in special populations, and improve the success rates of preclinical and clinical trials. Their approach emphasizes fit-for-purpose solutions and iterative integration of bioanalytical data with predictive modeling, providing customers with affordable, high-quality support that spans the entire lifecycle of drug development from early discovery stages to late-stage clinical evaluation.
Inquire about this partnering listing
Industry applications
delivered to your inbox.